Literature DB >> 30703575

Assessment of muscle mass depletion in chronic liver disease: Dual-energy x-ray absorptiometry compared with computed tomography.

Catarina Lindqvist1, Torkel B Brismar2, Ammar Majeed3, Staffan Wahlin4.   

Abstract

OBJECTIVES: The aim of this study was to perform intermethod comparisons between the following three measures of muscle mass depletion in patients eligible for liver transplantation: 1) fat-free mass index (FFMI) measured by dual-energy x-ray absorptiometry (DXA), 2) appendicular skeletal muscle mass index (ASMI) measured by DXA, and 3) skeletal muscle index (SMI) measured at the third lumbar level by computed tomography (CT).
METHODS: The medical records of patients who received liver transplants between 2009 and 2012 at Karolinska University Hospital were retrospectively reviewed. Adult patients with a chronic liver disease who had both DXA and CT scans performed within a 30-d period during their pretransplant workup were included.
RESULTS: Appendicular skeletal muscle mass index measured by DXA (ASMIDXA) and skeletal mass index measured by computed tomography (SMICT) provide similar results when assessing the presence of muscle mass depletion in patients with chronic liver diseases and FFMIDXA can be falsely high in patients with ascites. Both ASMIDXA and SMICT thus appear to be useful methods in the pretransplant evaluation of muscle mass depletion both for patients with and without ascites.
CONCLUSIONS: ASMI measured with DXA is a useful alternative method to SMI measured with CT when a CT scan is not clinically indicated or available.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ASMI; Body composition; FFMI; Liver transplantation; Nutritional assessment; SMI; Sarcopenia

Mesh:

Year:  2018        PMID: 30703575     DOI: 10.1016/j.nut.2018.10.031

Source DB:  PubMed          Journal:  Nutrition        ISSN: 0899-9007            Impact factor:   4.008


  7 in total

1.  Appendicular Skeletal Muscle Index and HbA1c Evaluate Liver Steatosis in Patients With Metabolic Associated Fatty Liver Disease.

Authors:  Rui Jin; Xiaoxiao Wang; Xiaohe Li; Jia Yang; Baiyi Liu; Lai Wei; Feng Liu; Huiying Rao
Journal:  Front Med (Lausanne)       Date:  2022-07-06

Review 2.  Sarcopenia and frailty in decompensated cirrhosis.

Authors:  Puneeta Tandon; Aldo J Montano-Loza; Jennifer C Lai; Srinivasan Dasarathy; Manuela Merli
Journal:  J Hepatol       Date:  2021-07       Impact factor: 30.083

3.  Association between Sarcopenia and Depression in Patients with Chronic Liver Diseases.

Authors:  Hiroki Nishikawa; Hirayuki Enomoto; Kazunori Yoh; Yoshinori Iwata; Yoshiyuki Sakai; Kyohei Kishino; Naoto Ikeda; Tomoyuki Takashima; Nobuhiro Aizawa; Ryo Takata; Kunihiro Hasegawa; Noriko Ishii; Yukihisa Yuri; Takashi Nishimura; Hiroko Iijima; Shuhei Nishiguchi
Journal:  J Clin Med       Date:  2019-05-08       Impact factor: 4.241

Review 4.  Radiologic Definition of Sarcopenia in Chronic Liver Disease.

Authors:  Chul-Min Lee; Bo Kyeong Kang; Mimi Kim
Journal:  Life (Basel)       Date:  2021-01-25

Review 5.  Definition of Sarcopenia in Chronic Liver Disease.

Authors:  Seong Wan Son; Do Seon Song; U Im Chang; Jin Mo Yang
Journal:  Life (Basel)       Date:  2021-04-16

6.  Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.

Authors:  Jennifer C Lai; Puneeta Tandon; William Bernal; Elliot B Tapper; Udeme Ekong; Srinivasan Dasarathy; Elizabeth J Carey
Journal:  Hepatology       Date:  2021-09       Impact factor: 17.298

7.  Validation of cutoffs for skeletal muscle mass index based on computed tomography analysis against dual energy X-ray absorptiometry in patients with cirrhosis: the KIRRHOS study.

Authors:  Alexandra Georgiou; Georgios V Papatheodoridis; Alexandra Alexopoulou; Melanie Deutsch; Ioannis Vlachogiannakos; Panagiota Ioannidou; Maria-Vasiliki Papageorgiou; Nikolaos Papadopoulos; Mary Yannakoulia; Meropi D Kontogianni
Journal:  Ann Gastroenterol       Date:  2019-11-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.